NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 202)
Posted On: 12/27/2018 4:55:03 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) New Laboratory Construction Advances Rapidly
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a biotechnology company and drug delivery platform innovator, has submitted a Health Canada research application for a license to allow in-house research to be conducted at its Kelowna-based laboratory. A recent article further discussing the company reads, “Lexaria submitted its research application under Health Canada’s Cannabis Tracking and Licensing System for the operation of a research and development (R&D) laboratory to work with cannabinoids within the company’s new Kelowna head office, now under construction. In fact, Lexaria will commence experimental work on nicotine formulations, NSAIDs, vitamins and other bioactive compounds of interest after the completion of this laboratory facility. … The construction of the new head office and laboratory is advancing fast. Lexaria expects to occupy the new facility by the end of January 2019. The company is recruiting more staff to prepare for more wide-ranging operations. Moreover, Lexaria has taken delivery of specific equipment in a separate location where it is uniting known nano-emulsification processes with its DehydraTECH drug delivery platform for enhanced performance characteristics. This work will also transition to the Kelowna laboratory upon the facility being operational and licensed.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a biotechnology company and drug delivery platform innovator, has submitted a Health Canada research application for a license to allow in-house research to be conducted at its Kelowna-based laboratory. A recent article further discussing the company reads, “Lexaria submitted its research application under Health Canada’s Cannabis Tracking and Licensing System for the operation of a research and development (R&D) laboratory to work with cannabinoids within the company’s new Kelowna head office, now under construction. In fact, Lexaria will commence experimental work on nicotine formulations, NSAIDs, vitamins and other bioactive compounds of interest after the completion of this laboratory facility. … The construction of the new head office and laboratory is advancing fast. Lexaria expects to occupy the new facility by the end of January 2019. The company is recruiting more staff to prepare for more wide-ranging operations. Moreover, Lexaria has taken delivery of specific equipment in a separate location where it is uniting known nano-emulsification processes with its DehydraTECH drug delivery platform for enhanced performance characteristics. This work will also transition to the Kelowna laboratory upon the facility being operational and licensed.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)